Asthma, Allergic Completed Phase 4 Trials for Omalizumab (DB00043)
Also known as: Atopic Asthma / Allergic Asthma / Asthma extrinsic / Extrinsic asthma / Asthma / Asthma, unspecified / Asthma bronchial / Asthma NOS / Asthmatic / Br. asthma / Bronchitic asthma
| Indication | Status | Phase |
|---|---|---|
| DBCOND0047182 (Asthma, Allergic) | Completed | 4 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00283504 | A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy | Diagnostic | |
| NCT02023151 | Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils | Treatment | |
| NCT00267202 | Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma | Treatment | |
| NCT00670930 | Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists | Treatment | |
| NCT00813748 | Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing | ||
| NCT01125748 | A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy | Treatment |